Phase 1 Relapsed or Refractory Multiple Myeloma Clinical Trials
13 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–13 of 13 trials
Recruiting
Phase 1
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC80 enrolled15 locationsNCT06604715
Recruiting
Phase 1
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC180 enrolled29 locationsNCT05652335
Recruiting
Phase 1Phase 2
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.166 enrolled10 locationsNCT07116616
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Relapsed or Refractory Multiple Myeloma
Genentech, Inc.120 enrolled14 locationsNCT05927571
Recruiting
Phase 1
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.130 enrolled11 locationsNCT06375044
Recruiting
Phase 1
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Excyte Biopharma Ltd70 enrolled12 locationsNCT06574568
Recruiting
Phase 1
Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
O&D BioTech Group CO., Limited18 enrolled1 locationNCT07369895
Recruiting
Phase 1
Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Relapsed or Refractory Multiple Myeloma (RRMM)
Beijing GoBroad Hospital18 enrolled1 locationNCT07003555
Recruiting
Phase 1
Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Relapsed or Refractory Multiple Myeloma (RRMM)
Beijing GoBroad Hospital18 enrolled1 locationNCT07003568
Recruiting
Phase 1
YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China12 enrolled1 locationNCT05913804
Recruiting
Phase 1Phase 2
Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Zhejiang ACEA Pharmaceutical Co. Ltd.84 enrolled4 locationsNCT05565807
Recruiting
Phase 1Phase 2
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
Chengdu Zenitar Biomedical Technology Co., Ltd144 enrolled1 locationNCT06484829
Recruiting
Phase 1Phase 2
A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
Relapsed or Refractory Multiple Myeloma
Beijing Mabworks Biotech Co., Ltd.154 enrolled1 locationNCT06232096